Changeflow GovPing Pharma & Drug Safety Mesoporous Nano-Magnesium Oxide for Drug Loading
Routine Notice Added Final

Mesoporous Nano-Magnesium Oxide for Drug Loading

Email

Summary

The USPTO has published a patent application for a mesoporous nano-magnesium oxide material designed for drug loading. The application details the material's properties, including particle size and pore structure, and outlines a preparation method involving magnesium oxalate and CTAB.

What changed

This document is a USPTO patent application (US20260083680A1) for a novel mesoporous nano-magnesium oxide material intended for drug loading. The application specifies particle size (50-150 nm), pore size (2-20 nm), and a positive Zeta potential in absolute ethanol. It also describes a preparation method involving calcining magnesium oxalate and CTAB at specific temperatures.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it may inform future research and development in drug delivery systems. Companies in the pharmaceutical sector may wish to review this application for potential intellectual property insights or to understand emerging technologies in drug formulation and delivery.

Source document (simplified)

← USPTO Patent Applications

MESOPOROUS NANO-MAGNESIUM OXIDE FOR DRUG LOADING AND PREPARATION METHOD THEREOF

Application US20260083680A1 Kind: A1 Mar 26, 2026

Assignee

SHANGHAI INSTITUTE OF TECHNOLOGY

Inventors

Chun XU

Abstract

A mesoporous nano-magnesium oxide for drug loading and a preparation method thereof are provided. The mesoporous nano-magnesium oxide particle has a particle size of 50 nm to 150 nm, and includes abundant mesoporous structures with a pore size of 2 nm to 20 nm. A surface of the particle has a positive potential in absolute ethanol, with a Zeta potential distribution of 10 mV to 100 mV. The preparation method includes: preparing a mixture of magnesium oxalate and CTAB as a precursor; adding the precursor to a quartz crucible, and placing the quartz crucible in a muffle furnace; calcining at 200℃ for 1 h to make the CTAB in the mixture completely decomposed to produce pure magnesium oxalate; and heating to 530°C, and calcining for 1 h to 6 h to make the magnesium oxalate fully decomposed to produce the nano-magnesium oxide microparticle.

CPC Classifications

A61K 9/5115 A61K 9/5192

Filing Date

2025-08-18

Application No.

19302131

View original document →

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083680A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Loading Drug Formulation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
FDA 21 CFR Part 11
Topics
Drug Delivery Nanotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.